CoChat

Gene Therapy in Ophthalmology: Validation on Cultured Retinal Cells and Explants from Postmortem Human Eyes

Fradot, Mathias, Busskamp, Volker, Forster, Valérie, Cronin, Thérèse, Léveillard, Thierry, Bennett, Jean, Sahel, José-Alain, Roska, Botond, Picaud, Serge · 2011 · Human Gene Therapy
Cited by 51

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Gene therapy studies in primates can provide important information regarding vector tropism, specific cellular expression, biodistribution, and safety prior to clinical trials. In this study, we report the assessment of transduction efficiency of recombinant adeno-associated virus (rAAV) vectors using human postmortem retina. Transductions were performed using two in vitro models prepared from human tissue: dissociated cell cultures and retinal explants. These models were used to assess cellular tropism and selectivity of rAAV vectors encoding for fluorescent proteins under the control of different promoters. These promoters were a ubiquitous cytomegalovirus promoter and a cell type–specific promoter targeting expression in ON bipolar cells. The results demonstrate that this in vitro approach can limit the use of living primates for the validation of gene therapy in vision and ophthalmology. Fradot and colleagues propose a new ex vivo approach for the preclinical assessment of gene transfer efficacy in the retina. The authors use human postmortem retinas to generate two in vitro models prepared from human tissue: dissociated cell cultures and retinal explants. These models were used to assess cellular tropism and selectivity of rAAV vectors encoding fluorescent proteins under the control of different promoters. The authors claim that this work paves the way for the wider use of postmortem human retina in other studies, even if these models cannot fully replace in vivo testing in primates.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.2010.157

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis

    Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×

    “Recent clinical trials have validated gene therapy for the treatment of an inherited blinding disease previously considered incurable (Bainbridge and Ali, 2008; Cideciyan et al., 2008; Maguire et al., 2008).”
    Self-citation
  • Effect of gene therapy on visual function in Leber’s congenital amaurosis

    Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 2×

    “First clinical evaluations indicate a gain of visual performance and an absence of side effects, supporting the safety and efficiency of recombinant adeno-associated virus (rAAV) vectors for retinal disease treatment (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008, 2009; Cideciyan et al., 2009).”
  • Gene therapy restores vision in a canine model of childhood blindness

    Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×

    “Efficacy was demonstrated in transgenic and natural murine models for LCA2 (Dejneka et al ., 2004; Lai et al ., 2004; Pang et al ., 2006), as well as in a natural occurring canine model of the disease, the Briard dog (Acland et al ., 2001; Le Meur et al ., 2007).”
    Self-citation
  • Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial

    Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954 · cited 1×

    “…indicate a gain of visual performance and an absence of side effects, supporting the safety and efficiency of recombinant adeno-associated virus (rAAV) vectors for retinal disease treatment (Bainbridge et al ., 2008; Hauswirth et al ., 2008; Maguire et al ., 2008, 2009; Cide-ciyan et al ., 2009).”
  • Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial

    Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 1×

    “…indicate a gain of visual performance and an absence of side effects, supporting the safety and efficiency of recombinant adeno-associated virus (rAAV) vectors for retinal disease treatment (Bainbridge et al ., 2008; Hauswirth et al ., 2008; Maguire et al ., 2008, 2009; Cide-ciyan et al ., 2009).”
    Self-citation

Show all 5 references

Cited by

Metadata

Authors
Fradot, M., Busskamp, V., Forster, V., Cronin, T., Léveillard, T., Bennett, J., Sahel, J.-A., Roska, B., & Picaud, S.
Venue
Human Gene Therapy
Published
2011-05
Volume
22
Issue
5
Pages
587-593
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2016197640
Cited by
51
References
5
FWCI
1.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.